Dementia with Lewy Bodies Epidemiology Forecast 2026-2035

Dementia with Lewy bodies is a progressive neurodegenerative disorder marked by cognitive decline, visual hallucinations, fluctuating alertness, and Parkinsonian motor features. As per Ece Bayram et al., 2023, it accounts for approximately 4.2 percent of dementia cases in community settings and 7.5% in clinical populations. According to the dementia with Lewy bodies epidemiology forecast, it represents a significant and growing global burden.

Dementia with Lewy Bodies Epidemiology Forecast Report Coverage

The analyst's “Dementia with Lewy Bodies Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of dementia with Lewy bodies. It projects the future incidence and prevalence rates of dementia with Lewy bodies cases across various populations. The study covers age, gender, and type as major determinants of the dementia with Lewy bodies population. The report highlights patterns in the prevalence of dementia with Lewy bodies over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of dementia with Lewy bodies in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Dementia with Lewy Bodies Understanding: Disease Overview

Dementia with Lewy bodies is a progressive neurodegenerative condition characterized by abnormal deposits of alpha-synuclein protein, known as Lewy bodies, in the brain. It affects cognitive function, movement, behavior, and sleep. The disease typically occurs due to the degeneration of neurons in areas controlling memory, thinking, and motor skills. It shares features with parkinson's disease and alzheimer's disease. There are no formally distinct subtypes, but it is often classified based on whether dementia appears before or after motor symptoms. Clinical presentation varies, including fluctuating cognition, visual hallucinations, and parkinsonism.

Dementia with Lewy Bodies Epidemiology Perspective

The dementia with Lewy bodies epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for dementia with Lewy bodies epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for dementia with Lewy bodies and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Sonja W Scholz et al., dementia with Lewy bodies shows a median diagnosis age of about 76 years, with symptoms typically beginning after 50 years. Incidence is higher in men, especially over 60 years, and frequent misdiagnosis as psychiatric or other dementias leads to an underestimation of true epidemiological burden.
• According to Shannon Y. Chiu et al., sex differences are evident in dementia with Lewy bodies, with men showing higher rates of parkinsonism while women present later, with greater cognitive impairment at diagnosis. Women more often exhibit mixed pathology with alzheimer’s disease, and progression patterns vary across sexes.
• According to Leila Lotfi et al., dementia with Lewy Bodies is the second most common neurodegenerative dementia after alzheimer’s disease, affecting approximately 0.4% of individuals over 65 annually. It is more frequently diagnosed in men and usually appears after age of 50 years, reflecting its classification as a synucleinopathy.
• According to Janice Taylor et al., dementia with Lewy Bodies accounts for about 4.2% of dementia diagnoses in community populations, while neuropathological studies suggest prevalence may reach 15%. High misdiagnosis rates, along with heterogeneous cognitive and motor symptoms and overlapping alzheimer’s pathology, contribute to variability in reported epidemiological estimates.

Country-wise Dementia with Lewy Bodies Epidemiology

The dementia with Lewy bodies epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across major regions, according to Marwan N. Sabbagh et al., 2023, dementia with Lewy bodies represents approximately 3% to 7% of dementia cases globally, with incidence ranging from 0.5 to 1.6 per 1,000 person-years and higher prevalence in older populations. In the United States, about 1.4 million individuals live with Lewy body dementia, while in India, dementia with Lewy bodies accounts for an estimated 1.0% to 8.9% of dementia diagnoses, as per Kirushnakumar H. P. et al., 2024, reflecting variability across healthcare systems and diagnostic practices.

Dementia with Lewy Bodies: Treatment Overview

Dementia with Lewy bodies management focuses on symptomatic relief, as there is no cure. Cholinesterase inhibitors such as Rivastigmine and Donepezil are commonly used to improve cognition and reduce hallucinations. Motor symptoms may be treated cautiously with Levodopa, although patients can be sensitive to side effects. Antipsychotics like quetiapine may be prescribed at low doses for severe hallucinations, with careful monitoring. Non-pharmacological approaches, including cognitive therapy, physical activity, sleep management, and caregiver support, are also essential to improve quality of life and slow functional decline.

Key Questions Answered

• What are the key findings of dementia with Lewy bodies epidemiology in the 8 major markets?
• What will be the total number of patients with dementia with Lewy bodies across the 8 major markets during the forecast period?
• What was the country-wise dementia with Lewy bodies epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of dementia with Lewy bodies patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of dementia with Lewy bodies during the forecast period of 2026-2035?
• What are the currently available treatments for dementia with Lewy bodies?
• What are the risks, signs, symptoms, and unmet needs of dementia with Lewy bodies?

Scope of the Dementia with Lewy Bodies Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of dementia with Lewy bodies based on several factors.
• Dementia with Lewy Bodies Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The dementia with Lewy bodies report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.